- Home
- DGII vs SNDX Comparison
DGII vs SNDX Comparison
Compare DGII & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGII
- SNDX
- Stock Information
- Founded
- DGII 1985
- SNDX 2005
- Country
- DGII United States
- SNDX United States
- Employees
- DGII N/A
- SNDX N/A
- Industry
- DGII Computer peripheral equipment
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- DGII Technology
- SNDX Health Care
- Exchange
- DGII Nasdaq
- SNDX Nasdaq
- Market Cap
- DGII 1.1B
- SNDX 1.1B
- IPO Year
- DGII N/A
- SNDX 2016
- Fundamental
- Price
- DGII $30.49
- SNDX $13.08
- Analyst Decision
- DGII Buy
- SNDX Strong Buy
- Analyst Count
- DGII 5
- SNDX 10
- Target Price
- DGII $34.80
- SNDX $36.20
- AVG Volume (30 Days)
- DGII 235.7K
- SNDX 2.7M
- Earning Date
- DGII 01-29-2025
- SNDX 02-25-2025
- Dividend Yield
- DGII N/A
- SNDX N/A
- EPS Growth
- DGII N/A
- SNDX N/A
- EPS
- DGII 0.61
- SNDX N/A
- Revenue
- DGII $424,046,000.00
- SNDX $16,000,000.00
- Revenue This Year
- DGII $2.01
- SNDX N/A
- Revenue Next Year
- DGII $5.11
- SNDX $14.15
- P/E Ratio
- DGII $49.95
- SNDX N/A
- Revenue Growth
- DGII N/A
- SNDX N/A
- 52 Week Low
- DGII $20.17
- SNDX $12.06
- 52 Week High
- DGII $34.82
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- DGII 49.91
- SNDX 41.29
- Support Level
- DGII $27.92
- SNDX $12.40
- Resistance Level
- DGII $30.39
- SNDX $13.16
- Average True Range (ATR)
- DGII 0.85
- SNDX 0.65
- MACD
- DGII 0.12
- SNDX 0.10
- Stochastic Oscillator
- DGII 81.85
- SNDX 39.38
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.